Oberadilol
Oberadilol (CID-3047798) is a Phosphodiesterase III inhibitor, non-selective β-adrenergic receptor blocker, vasodilator and positive inotropic agent. Oberadilol reduces left ventricular end-diastolic volume. Oberadilol is used in research related to chronic congestive heart failure and SARS-CoV-2 infection.
For research use only. We do not sell to patients.
- CAS No.: 114856-44-9
- Formula: C25H30ClN5O3
- Molecular Weight:483.99
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Adrenergic Receptor Isoforms
More
Biological Activity
|
PDE Ⅲ |
β adrenergic receptor |
Oberadilol is a pyridazinone derivative with vasodilatory, β-adrenergic blocking, and type III phosphodiesterase inhibitory activities[1].
Oberadilol reduces left ventricular end-diastolic volume and tends to increase ejection fraction[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 114856-44-9
-
Molecular Weight 483.99
-
Formula C25H30ClN5O3
-
SMILES
N#CC1=CC=C(Cl)C=C1OCC(O)CNC(C)(C)CNC2=CC=C(C(C(C)C3)=NNC3=O)C=C2
-
Synonyms
CID-3047798
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Araki S, et al. Cardiac and hemodynamic effects of TZC-5665, a novel pyridazinone derivative, and its metabolite in humans and dogs. General pharmacology. 1997 Apr;28(4):545-53. [Content Brief]
[3]. Srivastava A, et al. Exploring nature's bounty: identification of Withania somnifera as a promising source of therapeutic agents against COVID-19 by virtual screening and in silico evaluation. J Biomol Struct Dyn. 2022 Mar;40(4):1858-1908. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- Oberadilol
- 114856-44-9
- CID-3047798
- CID3047798
- CID 3047798
- Phosphodiesterase (PDE)
- Adrenergic Receptor
- SARS-CoV
- protease inhibitor
- enzyme inhibitor
- chronic congestive heart failure
- GPCR ligand
- COVID-19
- SARS-CoV main protease
- phosphodiesterase-III
- β-adrenergic receptor
- Lipinski's rule of five
- SARS-CoV-2 main protease
- Inhibitor
- inhibitor
- inhibit